NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday that its second quarter revenues for fiscal year 2015 declined 10 percent year over year.

Myriad also substantially lowered its guidance for Fiscal Year 2015, leading to a drop in its stock on Wednesday morning.

For the three months ended Dec. 31, the Salt Lake City-based molecular diagnostics firm had total revenues of $184.4 million compared to revenues of $204.1 million in Q2 2014. The revenues beat the consensus Wall Street estimate of $183.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.